RxDoctor Payments Data

Tanya Pandya

Family Medicine · Suwanee, GANPI 1639354434

Payments from drug & device makers

$10,352in general payments, 2019–2025

Across 553 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Amgen$877
  • Lilly USA, LLC$582
  • Inspire Medical Systems, Inc.$421
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$10,20499%
  • Education$1481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,352 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$450,258
Medicare patients
761
Services billed
12,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf137$42,824
ShingrixVaricella-Zoster Ge/As01b/Pf79$17,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,162
MounjaroTirzepatide12$12,283
Boostrix TdapDiphth,pertuss(Acell),tet Vac52$3,581
Liothyronine Sodium35$1,759
Levothyroxine Sodium80$759
Rosuvastatin Calcium53$589
Atorvastatin Calcium58$584
Gabapentin31$536
Ibandronate Sodium13$522
Ezetimibe22$502
Trazodone Hcl28$431
Novolog FlexpenInsulin Aspart12$351
Escitalopram Oxalate24$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Trelegy Ellipta$1,153$75,407237 claims
Lilly USA, LLCMounjaro$582$12,28312 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$75980 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →